iovance.com (IOVA): Price-to-Projected Revenue Ratio

IOVA (Iovance Biotherapeutics Inc) - company brandmark

Iovance Biotherapeutics (IOVA) has established a unique TIL-cell production network by integrating manufacturing plants with hospitals. The company is currently rapidly scaling its capacity to meet the growing demand for its innovative drug. Competent management has successfully navigated the complexities of the FDA. This GURU.Markets chart includes a forward P/S valuation metric, which currently stands at 9.50.

IOVA Iovance Biotherapeutics Inc: Market Cap to Future Revenue Ratio in the range 08/13/2023 - 11/15/2026

Analytical breakdowns for Iovance Biotherapeutics (IOVA)

- stock price and consensus target price:
Stock Quotes Iovance Biotherapeutics Inc|IOVA - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Iovance|IOVA - Business Value
- book value of equity indicators:
Net Assets per Single Share Iovance Biotherapeutics|IOVA - Total Stockholders' Equity|Market Cap to Net Assets Ratio iovance.com|IOVA - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Iovance Biotherapeutics|IOVA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Iovance Biotherapeutics, Inc.|IOVA - Aggregate Debt Obligations|Debts to Book Capitalization Iovance Corp|IOVA - Long-Term Debt|Company Short-Term Debt Iovance Biotherapeutics|Quick Ratio iovance.com
- business earnings and investment ratios data:
IOVA - Net Profit|Expected Profit Iovance Biotherapeutics|IOVA - Market Cap to Net Income|Projected Price to Earnings Iovance Biotherapeutics Inc|IOVA - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Iovance|IOVA - Operating income before deduction of amortization|Earnings per share for the last twelve months Iovance Biotherapeutics|IOVA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months iovance.com|IOVA - Earnings per share growth in current year|Earnings growth forecast for next year Iovance Biotherapeutics
- revenue and sales details:
IOVA - Revenue and Sales Volume|Company Projected Revenue Iovance Biotherapeutics|IOVA - Market Cap to Revenue Ratio|Forward P/S Multiple Iovance Biotherapeutics Inc|IOVA - Revenue Growth YoY (Last 12 Months)
Summary company analysis:iovance.com IOVA
Manufactured products of Iovance Corp

Investors determine an asset's margin of safety through the ratio of market value to projected revenue. The specifics of Iovance Biotherapeutics (IOVA) cell immunotherapy provide macro-stability, as demand is driven by medical protocols rather than the economic cycle. By analyzing the dynamics of the expected P/S ratio, one can identify overbought conditions or growth potential amid changes in liquidity. This indicator is critical for valuing high-tech biotechnology companies.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IMTX|XNCR - Projected Price to Revenue|Forward Price-to-Revenue Multiple CMPX (Compass Bio)|Price to Expected Revenue Ratio REPL|Forward P/S Multiple LYEL (Lyell Immunopharma, Inc.)|Forward Price to Sales IPHA|Pyxis - Forward P/S Multiple|Market Cap to Future Revenue Ratio Compugen|IO Biotech, Inc. (IOBT) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc. - Forward Price to Sales|INKT (minktherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple werewolftx.com|Price-to-Projected Revenue Ratio immixbio.com (IMMX)|ALXO: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP